Menu Search
Equities

Viking Therapeutics Inc

1VT:BER

Viking Therapeutics Inc

Actions
  • Price (EUR)49.65
  • Today's Change0.000 / 0.00%
  • Shares traded60.00
  • 1 Year change+374.44%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 20:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.

  • Revenue in USD (TTM)0.00
  • Net income in USD-99.15m
  • Incorporated2012
  • Employees33.00
  • Location
    Viking Therapeutics Inc9920 Pacific Heights Blvd, Suite 350SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 704-4660
  • Fax+1 (302) 636-5454
  • Websitehttps://vikingtherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.